The group's principal activity is to research, develop and commercialize drugs and develop therapeutic products that advance therapy, improve health and enrich lives. The group's focus is toward anti-infective drugs, with two product candidates in clinical development: mbi 226 for preventing catheter-related bloodstream infections (phase iii) and mbi 594an for treating acne (phase ii). Currently, the group has no products or license revenues. The group operates in Canada.
